Wegovy semaglutide tablets.
Michael Siluk | Common Pictures Group | Getty Pictures
Novo Nordisk on Tuesday launched a multi-month subscription program for its Wegovy weight problems drug merchandise that goals to make sure cash-paying sufferers see decrease, “predictable” month-to-month costs.
Eligible sufferers can select between three-, six- or 12-month subscriptions for the Wegovy injection or the 2 highest doses of the newly launched tablet beneath the identical model title. Longer plans supply decrease month-to-month pricing, and the corporate expects folks to save lots of as much as $1,200 a 12 months on the injection and as a lot as $600 a 12 months on the tablet, relative to paying for his or her particular person dose every month, in keeping with a Novo launch.
Sufferers can anticipate to pay flat month-to-month costs, even when they transfer to totally different doses, the corporate stated. The subscription program will probably be accessible beginning Tuesday on a number of of Novo’s telehealth companions, together with Ro, WeightWatchers and LifeMD. Sesame, Hims & Hers and extra are anticipated to be added quickly.
The primary-of-its-kind providing is “a possibility to assist sufferers not solely begin however keep on remedy and assist them handle the ups and downs of a number of the pricing concerns,” regardless if they’re beginning remedy or are at the moment taking the drug, stated Ed Cinca, Novo’s head of selling and affected person options.
Incapability to remain on GLP-1s is a longstanding difficulty attributable to elements akin to problem accessing the medicine and gastrointestinal uncomfortable side effects, with one 2025 examine estimating that round 65% of sufferers with weight problems cease remedy inside a 12 months.
Wegovy subscription costs and estimated financial savings
Injection subscription plans (0.25, 0.5, 1.7 and a pair of.4 milligram doses)
- 3-month: $329 per 30 days, financial savings of $240 per 12 months
- 6-month: $299 per 30 days, financial savings of $600 per 12 months
- 12-month: $249 per 30 days, financial savings of $1,200 per 12 months
Capsule subscription plans (9 and 25 milligram doses)
- 3-month: $289 per 30 days, financial savings of $120 per 12 months
- 6-month: $269 per 30 days, financial savings of $360 per 12 months
- 12-month: $249 per 30 days, financial savings of $600 per 12 months
The brand new program additionally comes as Novo’s tablet, which has seen explosive uptake since its U.S. launch in January, is ready to face recent competitors from an upcoming oral GLP-1 from chief rival Eli Lilly later this 12 months. Lilly is at the moment the dominant participant within the branded GLP-1 market within the U.S., with an estimated 60% share, whereas Novo has about 39%.
The Wegovy tablet has largely been reaching individuals who did not beforehand take GLP-1 injections, making it essential for Novo to seize as many new sufferers as it might probably earlier than a competitor arrives.
As Novo Nordisk’s subscription plans launch, cash-paying sufferers can nonetheless pay $149 per 30 days for the decrease doses of the tablet, that are 1.5 and 4 milligrams. However beginning in September, the 4-milligram dose will price $199 per 30 days. In the meantime, the just lately authorised 7.2-milligram dose of Wegovy will probably be added to the subscription program at a later date.
Cinca emphasised that sufferers can decide out of the subscription whereas it is energetic in the event that they now not want to enroll.
“We need to assist sufferers establish a path that may assist them really feel snug about treating [obesity] in the long run,” he added.
Cinca stated Novo just isn’t but providing this system on its NovoCare direct-to-consumer pharmacy, however added that there is “a possibility to judge how this goes after which construct it out” by means of that platform over time.
